Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

• المؤلفون الرئيسيون: Victor Sokolov (مؤلف), Tatiana Yakovleva (مؤلف), Lulu Chu (مؤلف), Weifeng Tang (مؤلف), Peter J. Greasley (مؤلف), Susanne Johansson (مؤلف), Kirill Peskov (مؤلف), Gabriel Helmlinger (مؤلف), David W. Boulton (مؤلف), Robert C. Penland (مؤلف)
• التنسيق: كتاب
• منشور في: Wiley, 2020-04-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative systems pharmacology model of renal glucose filtrati...